Prot #GS-US-367-1172: A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting

Project: Research project

Project Details

StatusFinished
Effective start/end date12/2/1512/2/18

Funding

  • PRA Health Sciences (GS-US-367-1172)
  • Gilead Sciences, Inc. (GS-US-367-1172)